{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2012"],"condition":["Refractory wtKRAS metastatic colorectal cancer","Metastatic colorectal cancer"],"disease":["Refractory Wtkras Metastatic Colorectal Cancer","Metastatic Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2530498"],"location":["France"],"study_start_month":["5"],"keyword":["BIBW2992"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"A multicentric randomized phase II study evaluating dual targeting of the EGFR using the combination of cetuximab and afatinib versus cetuximab alone in patients with chemotherapy refractory wtKRAS metastatic colorectal cancer.","description":"Primary objectives: Non Progression rate at 6 months\nPrimary endpoints: The primary endpoint non progression rate will be presented by the percentage of patients without progression at 6 months with the 95% confidence interval.","dates":{"creation":"2012-05-15"},"accession":"2530498","cross_references":{"EU Clinical Trials Register":["2012-000167-25"]}}